Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022104 (
irritable bowel syndrome
)
8,033
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Irritable bowel syndrome
(
IBS
) is a common, heterogeneous disorder characterized by abdominal pain associated with changes in bowel habits. The pathogenesis of
IBS
is multifactorial and may relate to alterations in the gut microbiota, changes in visceral sensation and motility, and genetic and environmental factors. Administration of systemic antibiotics may increase the risk of
IBS
by altering gastrointestinal homeostasis. Therapeutic interventions for
IBS
with diarrhea that are thought to target alterations in the gut microbiota include the nonsystemic antibiotic rifaximin, the medical food serum-derived bovine immunoglobulin, prebiotics, probiotics, and dietary modification.
SYN
-010 is a modified-release statin formulation that reduces methane production by Methanobrevibacter smithii and is currently in development for the treatment of patients with constipation-predominant
IBS
. Use of these interventions in the management of patients with
IBS
may function to restore a healthy gut microbiota and ameliorate symptoms of
IBS
.
...
PMID:Gut Microbiota-Based Therapies for Irritable Bowel Syndrome. 2944 65
